PositoAI/ US/ TG Therapeutics, Inc.

TG Therapeutics, Inc.

NasdaqCM: TGTX · Healthcare

Positivity Index

#5,934 / 6,774

Global

#3,331 / 4,000

United States

Positivity Score

13,812

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

TG Therapeutics, Inc. — Overview & Financial Snapshot

TG Therapeutics, Inc. (NasdaqCM: TGTX) is a Healthcare company, ranked #5,934 of 6,774 companies globally and #3,331 of 4,000 in United States on PositoAI, with a Positivity Score of 13,812. Its market capitalisation is ₹76,814.52 Cr ($8.14B), P/E ratio is 19.3 and P/B ratio is 13.47. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

P/B Ratio 13.47

P/E Ratio 19.3

D/E Ratio 1.25

ROE 100.28%

Owes vs Owns ? 0.63× Moderate $0.63 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹259.57$2.75

Forward EPS ₹255.61$2.71

Beta 1.80

Market Cap ₹76,814.52 Cr$8.14B

What these numbers mean →

What does TG Therapeutics, Inc. do?

What is TG Therapeutics, Inc.'s P/E and P/B ratio?

TG Therapeutics, Inc. has a P/E ratio of 19.3 and a P/B ratio of 13.47.

What is TG Therapeutics, Inc.'s debt-to-equity ratio?

TG Therapeutics, Inc. has a debt-to-equity ratio of 1.25.

How much does TG Therapeutics, Inc. owe compared with what it owns?

TG Therapeutics, Inc. owes $0.63 for every $1 it owns (balance sheet Jun 2026), which is moderate.

What is TG Therapeutics, Inc.'s Positivity rank?

TG Therapeutics, Inc. is ranked #5,934 of 6,774 companies globally and #3,331 of 4,000 in United States on PositoAI, with a Positivity Score of 13,812.

Does TG Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for TG Therapeutics, Inc..

Where can I read the latest news about TG Therapeutics, Inc.?

Recent headlines about TG Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does TG Therapeutics, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of TG Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.